Oncotarget cover image

Oncotarget

Blog: Targeting Fatty Acid Binding Proteins in Multiple Myeloma

Sep 21, 2023
Learn about the potential of targeting fatty acid binding proteins (FABPs) as a therapeutic approach for multiple myeloma (MM), including their impact on MYC oncogene expression, mitochondrial function, DNA methylation patterns, and immune cell infiltration. FABPs, specifically FABP5, show promise as potential biomarkers and therapeutic targets for MM, improving patient outcomes.
05:14

Podcast summary created with Snipd AI

Quick takeaways

  • FABP5 expression is higher in multiple myeloma cells and targeting it may reduce MM cell growth, survival, and progression.
  • Further research is needed to optimize the use of FABP inhibitors in MM treatment and understand their interactions with other metabolic pathways and effects on bone remodeling.

Deep dives

FABP5 as a Therapeutic Target in Multiple Myeloma

Fatty acid binding protein 5 (FABP5) expression is higher in multiple myeloma (MM) cells compared to normal plasma cells. High FABP5 levels are associated with worse survival and progression in MM patients. FABP inhibitors can reduce MM cell growth, survival, and proliferation by affecting pathways such as the unfolded protein response, reactive oxygen species generation, MYC oncogene expression, mitochondrial function and metabolism, and DNA methylation patterns. Researchers suggest that targeting both tumor cell-derived and microenvironment-derived FABPs may be more effective for MM treatment. Further research is needed to understand the mechanisms of action and develop specific inhibitors.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner